Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/21610

Title: The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses
Authors: Vanmierlo, Tim
Creemers, Pim
Akkerman, Sven
van Duinen, Marlies
Sambeth, Anke
De Vry, Jochen
Uz, Tolga
Blokland, Arjan
Prickaerts, Jos
Issue Date: 2016
Citation: BEHAVIOURAL BRAIN RESEARCH, 303, p. 26-33
Abstract: Enhancement of central availability of the second messenger CAMP is a promising approach to improve cognitive function. Pharmacological inhibition of phosphodiesterase type 4 (PDE4), a group of cAMP hydrolyzing enzymes in the brain, has been shown to improve cognitive performances in rodents and monkeys. However, inhibition of PDE4 is generally associated with severe emetic side-effects. Roflumilast, an FDA-approved PDE4 inhibitor for treatment of chronic obstructive pulmonary disease (COPD), is yielding only mild emetic side effects. In the present study we investigate the potential of roflumilast as a cognition enhancer and to determine the potential coinciding emetic response in comparison to rolipram, a classic PDE4 inhibitor with pronounced emetic effects. Cognition enhancement was evaluated in mice and it was found that both roflumilast and rolipram enhanced memory in an object location task (0.03 mg/kg), whereas only roflumilast was effective in a spatial Y-maze (0.1 mg/kg). Emetic potential was measured using competition of PDE4 inhibition for alpha 2-adrenergic receptor antagonism in which recovery from xylazine/ketamine-mediated anesthesia is used as a surrogate marker. While rolipram displayed emetic properties at a dose 10 times the memory-enhancing dose, roflumilast only showed increased emetic-like properties at a dose 100 times the memory-enhancing dose. Moreover, combining sub-efficacious doses of the approved cognition enhancer donepezil and roflumilast, which did not improve memory when given alone, fully restored object recognition memory deficit in rats induced by the muscarinic receptor antagonist scopolamine. These findings suggest that roflumilast offers a more favorable window for treatment of cognitive deficits compared to rolipram. (C) 2016 Elsevier B.V. All rights reserved.
Notes: [Vanmierlo, Tim; Creemers, Pim; Akkerman, Sven; van Duinen, Marlies; De Vry, Jochen; Prickaerts, Jos] Maastricht Univ, Sch Mental Hlth & Neurosci, Dept Psychiat & Neuropsychol, POB 616, NL-6200 MD Maastricht, Netherlands. [Vanmierlo, Tim] Hasselt Univ, BIOMED, Dept Immunol & Biochem, Hasselt, Belgium. [Sambeth, Anke; Blokland, Arjan] Maastricht Univ, Dept Neuropsychol & Psychopharmacol, NL-6200 MD Maastricht, Netherlands. [Uz, Tolga] Takeda Dev Ctr Amer Inc, Expt Med CNS, Deerfield, IL USA. [Creemers, Pim] Boston Sci Grp Plc, Dept Neuromodulat, Clin, Maastricht, Netherlands.
URI: http://hdl.handle.net/1942/21610
DOI: 10.1016/j.bbr.2016.01.031
ISI #: 000372688900004
ISSN: 0166-4328
Category: A1
Type: Journal Contribution
Validation: ecoom, 2017
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
published version1.08 MBAdobe PDF
Peer-reviewed author version775.49 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.